Search Results - "de Oliveira, Jose S R"

Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study by Kuruvilla, John, Ramchandren, Radhakrishnan, Santoro, Armando, Paszkiewicz-Kozik, Ewa, Gasiorowski, Robin, Johnson, Nathalie A, Fogliatto, Laura Maria, Goncalves, Iara, de Oliveira, Jose S R, Buccheri, Valeria, Perini, Guilherme F, Goldschmidt, Neta, Kriachok, Iryna, Dickinson, Michael, Komarnicki, Mieczyslaw, McDonald, Andrew, Ozcan, Muhit, Sekiguchi, Naohiro, Zhu, Ying, Nahar, Akash, Marinello, Patricia, Zinzani, Pier Luigi

“…PD-1 blockade via pembrolizumab monotherapy has shown antitumour activity and toxicity in patients with relapsed or refractory classical Hodgkin lymphoma…”
Get full text

Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma by Zinzani, Pier Luigi, Ramchandren, Radhakrishnan, Santoro, Armando, Paszkiewicz-Kozik, Ewa, Gasiorowski, Robin, Johnson, Nathalie A., de Oliveira, Jose S.R., Buccheri, Valeria, Perini, Guilherme Fleury, Dickinson, Michael, McDonald, Andrew, Özcan, Muhit, Sekiguchi, Naohiro, Zhu, Ying, Raut, Monika, Saretsky, Todd L., Nahar, Akash, Kuruvilla, John

“…KEYNOTE-204 (NCT02684292) demonstrated a progression-free survival advantage for pembrolizumab over brentuximab vedotin (BV) in patients who had relapsed or…”
Get full text

Requirement for PLCγ2 in IL-3 and GM-CSF-stimulated MEK/ERK phosphorylation in murine and human hematopoietic stem/progenitor cells by Leon, Carlos M.M.P., Barbosa, Christiano M.V., Justo, Giselle Z., Borelli, Primavera, Junior, José Dias Resende, de Oliveira, José S.R., Ferreira, Alice T., Paredes-Gamero, Edgar J.

“…Even though the involvement of intracellular Ca2+ (${\rm Ca}_{{\rm i}}^{{\rm 2 + }} $) in hematopoiesis has been previously demonstrated, the relationship…”
Get full text

Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin (BV) on Symptoms Associated with Health-Related Quality of Life (HRQoL) in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL) in the Randomized, Phase 3, Keynote-204 Study by Zinzani, Pier Luigi, Ramchandren, Radhakrishnan, Santoro, Armando, Paszkiewicz-Kozik, Ewa, Gasiorowski, Robin, Johnson, Nathalie A, Oliveira, José S. R. de, Buccheri, Valeria, Perini, Guilherme Fleury, Dickinson, Michael, McDonald, Andrew, Ozcan, Muhit, Sekiguchi, Naohiro, Raut, Monika, Giezek, Hilde, Nahar, Akash, Kuruvilla, John

“…Introduction: Patient-reported outcomes (PROs) in cHL are lacking, particularly those collected prospectively in clinical trials. Additionally, patients (pts)…”
Get full text